“A biotech backed by Merck, Eli Lilly and private equity group BlackRock says it has begun one of the first clinical trials in humans of a drug discovered using artificial intelligence to analyse a vast database of brain tissue.

Verge Genomics, which was founded by Alice Zhang, a 33-year-old former neuroscience doctoral student at University of California, told the Financial Times that it has dosed its first patient with a novel therapy named VRG50635 to target ALS, a neurodegenerative disease for which there is no known cure.”

via – FT.com